Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers | Citedby Results | Molecular Cancer Therapeutics | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers

Mol Cancer Ther (2022) 21 (2): 294–309.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Current and emerging approaches to noncompetitive AR inhibition

Christopher M. Riley
Jessica M. L. Elwood
Martyn C. Henry
Irene Hunter
J. Daniel Lopez‐Fernandez
Iain J. McEwan
Craig Jamieson

Medicinal Research Reviews (2023) 43 (5): 1701.

Rational drug design targeting intrinsically disordered proteins

Hanping Wang
Ruoyao Xiong
Luhua Lai

WIREs Computational Molecular Science (2023) 13 (6)

Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1

Jon K. Obst
Nasrin R. Mawji
Simon J. L. Teskey
Jun Wang
Marianne D. Sadar

Cancers (2022) 14 (2): 386.

Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy

Ahmed F. Abdel-Magid

ACS Medicinal Chemistry Letters (2022) 13 (9): 1408.